An efficient and secure agent code distribution service

2010 ◽  
pp. n/a-n/a
Author(s):  
J. Cucurull ◽  
G. Navarro-Arribas ◽  
R. Martí ◽  
S. Robles ◽  
J. Borrell
Keyword(s):  
1997 ◽  
Vol 6 (1) ◽  
pp. 3-27 ◽  
Author(s):  
Corinne Ancourt ◽  
Fabien Coelho ◽  
FranÇois Irigoin ◽  
Ronan Keryell

High Performance Fortran (HPF) was developed to support data parallel programming for single-instruction multiple-data (SIMD) and multiple-instruction multiple-data (MIMD) machines with distributed memory. The programmer is provided a familiar uniform logical address space and specifies the data distribution by directives. The compiler then exploits these directives to allocate arrays in the local memories, to assign computations to elementary processors, and to migrate data between processors when required. We show here that linear algebra is a powerful framework to encode HPF directives and to synthesize distributed code with space-efficient array allocation, tight loop bounds, and vectorized communications forINDEPENDENTloops. The generated code includes traditional optimizations such as guard elimination, message vectorization and aggregation, and overlap analysis. The systematic use of an affine framework makes it possible to prove the compilation scheme correct.


2013 ◽  
Vol 443 ◽  
pp. 546-550
Author(s):  
Guang Ya Li

The most important and concerned problem with the Internet electronic registration is security problem. This contribution uses conic curve method to verify the generating license in servers. In order to ensure the validity and security of license, the process of license distribution apply a verifiable code distribution scheme based on conic curve to make the electronic registration process more secure. In this paper, we propose a distributed electronic authentication scheme based on conic curves. As an alternative algebra curve technology, we believe conic deserves the further study in cryptography.


2021 ◽  
Author(s):  
Moataz Dowaidar

Silencing RNA (siRNA) is a promising next-generation approach to correcting genetic defects that predispose people to cancer. The move from the lab to the clinic as a standard cancer treatment still has a long way to go, with a number of limitations, including poor delivery, targeting and internalization efficiency, low stability, mutation susceptibility, quick renal clearance, and significant immunogenicity. In combination with existing chemotherapy therapies, SiRNA technology may also be employed, giving it a feasible choice for overcoming chemoresistance and enhancing apoptotic rates in a range of cancers. Codelivery of siRNA for genes involved in cancer progression, such as p53 and Bcl2 family genes, as well as genes involved in multidrug resistance, with current chemotherapeutic drugs such as doxorubicin and cisplatin, has shown incredible success in killing cancer cells. Nanoparticles can create a surface where several medications may be conjugated, allowing combination therapy. Nanoparticles can also aid by increasing the size of siRNA, which limits too rapid removal of glomerular filtration, blocking the 3 'end of siRNAs to protect against circulatory exonuclease damage, and boosting intestinal absorption. Several nanoparticles have been used, including liposomes, nanoemulsions, cationic polymers and dendrimers. However, the safety and biocompatibility of these particles remains a tough issue to resolve and should be considered in picking the proper nanoparticles. Overall, these applications provide chances to overcome cancer therapy challenges and assist to erase existing barriers to this global health concern in the near future.


Sign in / Sign up

Export Citation Format

Share Document